Pathway | Size | DE fractiona | Type | Possible relation to the cancer | Reference |
---|---|---|---|---|---|
GnRH signaling pathway | 78 | 37% | Endocrine system | Negative autocrine regulator | |
Complement and coagulation cascades | 56 | 54% | Immune system | Inflammation Metastatic and invasive properties | [80] |
MAPK signaling pathway | 199 | 38% | Signal transduction | Cell growth | - |
Fc epsilon RI signaling pathway | 63 | 44% | Immune system | Angiogenesis Inflammation | |
Apoptosis | 67 | 34% | Cell growth and death | Apoptosis | - |
ABC transporters | 34 | 24% | Membrane transport | Drug resistance | [81] |
Jak-STAT signaling pathway | 93 | 37% | Signal transduction | Cell growth | |
Drug metabolism - cytochrome P450 | 41 | 51% | Xenobiotics biodegradation and metabolism | Anticancer drugs topotecan and etoposide | [75] |
Drug metabolism - other enzymes | 28 | 46% | Xenobiotics biodegradation and metabolism | Anticancer drug irinotecan | [75] |
Histidine metabolism | 24 | 42% | Amino acid metabolism | Nutrition intake. Small cell lung cancer marker, DDC involved. | |
Tryptophan metabolism | 36 | 39% | Amino acid metabolism | As above | |
Phenylalanine metabolism | 13 | 54% | Amino acid metabolism | As above | |
Fatty acid metabolism | 37 | 38% | Lipid metabolism | Apoptosis. Therapeutic target | |
Basal cell carcinoma | 36 | 17% | Disease | Proliferation invasion through hedgehog signaling pathway | - |